Monopar Therapeutics (MNPR) PT Raised to $128 at Barclays
Tweet
Share
E-mailGet Alerts MNPR Hot Sheet
Price: $117.57 +5.04%
Rating Summary:
14 Buy, 2 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Rating Summary:
14 Buy, 2 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Join SI Premium – FREE
Barclays analyst Etzer Darout raised the price target on Monopar Therapeutics (NASDAQ: MNPR) to $128.00 (from $125.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Designer Brands (DBI) PT Lowered to $6 at UBS
- TETRA Technologies Inc. (TTI) PT Lowered to $10 at Northland
- Comstock Resources (CRK) PT Raised to $20 at Mizuho
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
